CA-NETAPP
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced cyber-resiliency capabilities that will equip customers to better protect and recover their data in the face of ransomware threats. NetApp is one of the first to integrate artificial intelligence (AI) and machine learning (ML) directly into enterprise primary storage to fight ransomware in real-time. The NetApp cyber-resiliency capabilities protect both primary and secondary data for organizations whether it is stored on-premises or in the cloud.
Cybercriminals are increasingly aiming ransomware attacks at critical infrastructure and supply chains where operational disruptions can cost millions of dollars, according to Forrester. As a result, 87 percent of C-suite and board-level executives ranked ransomware as a high, or the top, priority for their organization, according to the NetApp 2023 Data Complexity report. When cybercriminals breach perimeters, networks, and identities storage becomes the last line of defense for organizations’ most critical data. With the threat of ransomware looming, organizations need solutions that not only protect their data but also quickly recover lost data and return to normal operations. NetApp is updating its cyber-resiliency solutions and leveraging the power of AI to give customers confidence that their data will be safe and accessible when they need it.
“NetApp is taking an aggressive and proactive approach to protecting our customers’ data against cyber threats using artificial intelligence. We are the first storage vendor to explicitly and financially guarantee our data storage offerings against ransomware,” said Mignona Cote, CSO at NetApp. “Today, we are furthering that leadership with updates that make defending data comprehensive, continuous, and simple for our customers.”
NetApp is focused on designing data storage and management systems that maximize data protection and security while meeting data governance and compliance standards, with new updates that include:
- ONTAP Autonomous Ransomware Protection with Artificial Intelligence (ARP/AI) will spearhead the next generation of real-time enterprise storage ransomware protection, giving increased accuracy and performance required to detect and mitigate new, more sophisticated cyber threats. NetApp pioneered autonomous real-time detection of ransomware directly in primary enterprise storage three years ago. Now, NetApp will be leading the charge to use adaptive AI/ML models built directly into enterprise primary storage to look at file-level signals in real-time to detect even the newest ransomware attacks with planned 99%+ precision and recall. NetApp will be offering the first technology preview of ARP/AI within the next quarter.
- NetApp BlueXP Ransomware Protection, now in public preview, provides a single control plane to intelligently coordinate and execute an end-to-end, workload-centric ransomware defense. Customers can now identify and protect critical workload data with a single click, accurately and automatically detect and respond to a potential attack, and recover workloads within minutes, safeguarding their valuable data and minimizing costly disruption.
- Application-Aware Ransomware Protection via NetApp SnapCenter 5.0 offers immutable ransomware protection for applications. SnapCenter will now apply NetApp's leading ransomware protection technologies, previously used with unstructured data, to application-consistent backup. SnapCenter 5.0 includes support for key ONTAP features like tamperproof Snapshot copy locking, SnapLock protected volumes, and SnapMirror Business Continuity to enable more robust data protection for applications and virtual machines. SnapCenter 5.0 supports protection of applications on-premises with NetApp AFF, ASA, and FAS, as well as in the cloud.
- NetApp BlueXP Disaster Recovery, now generally available, offers seamless integration with VMware infrastructure and provides storage options for both on-premises and major public cloud environments. This comprehensive solution eliminates the need for separate standby disaster recovery (DR) infrastructure, reducing costs. With NetApp BlueXP disaster recovery, failover and failback processes are simplified, allowing smooth transitions from on-premises VMware infrastructure to the public cloud or to an on-premises data center.
- NetApp Keystone Ransomware Recovery Guarantee extends NetApp’s current Ransomware Recovery Guarantee to our leading storage-as-a-service offering, NetApp Keystone. With this guarantee, NetApp will warrant snapshot data recovery in the event of a ransomware attack. If snapshot data copies can’t be recovered through NetApp, we will offer compensation*.
“Today’s cybersecurity teams face the monumental task of protecting their companies’ data from ever-evolving threats, especially ransomware,” said Archana Venkatraman, Research Director, Cloud Data Management, IDC. “NetApp’s approach of delivering a secure, unified storage infrastructure makes storage foundational for ransomware protection and reduces the burden on cybersecurity teams. Companies looking to fortify their cyber resiliency and shifting protection left will increasingly look to vendors that take a secure-by-design approach and develop unified storage and data services.”
“Using NetApp in our Advanced Technology Center, we significantly simplified our replication process for VMware virtual machines and their underlying datastores to meet or exceed recovery benchmarks,” said Derek Elbert, Solutions Architect at WWT. “With NetApp’s solutions, we successfully established the recovery policies for cloud volumes workloads or virtual machines with no existing DR strategy, managing everything through NetApp BlueXP. This transforms how we operate disaster recovery for VMware.”
“To store sensitive genomics and health data, we have to use the right technology with layers of security built in,” said Mark Cowley, Deputy Director at Children’s Cancer Institute. “With NetApp, we can be very confident that we are sharing the right data only to authorized researchers. The last line of defense is your weakest web-based system, so we’ve implemented role-based access and added resilience to all of our tools.”
The latest cyber resiliency updates from NetApp empower organizations to proactively address cybersecurity threats in complex hybrid and multicloud environments, leveraging AI to identify threats and prevent disruptions to their operations.
To learn more about the NetApp cyber-resiliency offerings visit: https://www.netapp.com/cyber-resilience/
*Specific terms and conditions will apply. Customers must apply for coverage by the guarantee.
Additional Resources
About NetApp
NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305981204/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom